NCT00101036View on ClinicalTrials.gov

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder Cancer
Interventions
DRUG

lapatinib ditosylate

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

95817

UC Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00101036 - Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter